Tools
Tools
Lewis, JM and Sloan, Derek (2015) 'The role of delamanid in the treatment of drug-resistant tuberculosis'. Therapeutics and Clinical Risk Management, Vol 11, pp. 779-791.
|
Text
TCRM-71076-update-on-the-management-of-multidrug--resistant-tuberculosi_051315.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (464kB) | Preview |
Abstract
Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.
| Item Type: | Article |
|---|---|
| Subjects: | QW Microbiology and Immunology > QW 45 Microbial drug resistance. General or not elsewhere classified. WF Respiratory System > Tuberculosis > WF 200 Tuberculosis (General) |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.2147/TCRM.S71076 |
| Depositing User: | Jessica Jones |
| Date Deposited: | 08 Jan 2016 10:03 |
| Last Modified: | 06 Feb 2018 13:11 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/5481 |
Statistics
Actions (login required)
 |
Edit Item |